Oncopeptides AB (FRA:OND) EPS without NRI: €-0.08 (TTM As of Mar. 2026)


FRA:OND Oncopeptides AB FRA:OND
28 GF Score
Price €0.15
GF Value €0.38
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Oncopeptides AB EPS without NRI?

Oncopeptides AB FRA:OND +2.34% 28 EPS without NRI is €-0.08 as of Mar. 2026. GuruFocus rates FRA:OND with a GF Score™ of 28/100 and a GF Value™ of €0.38 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,166 Biotechnology companies, Oncopeptides AB ranks better than 63.38% on this metric.

Oncopeptides AB's earnings per share without non-recurring items for the three months ended in Mar. 2026 was €-0.01. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.08.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Oncopeptides AB's EPS without NRI or its related term are showing as below:

FRA:OND' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -96.3   Med: -25.6   Max: 48.6
Current: 27.4

FRA:OND's 3-Year EPS without NRI Growth Rate is ranked better than
63.38% of 1166 companies
in the Biotechnology industry
Industry Median: 16.65 vs FRA:OND: 27.40

Oncopeptides AB's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.08.

Oncopeptides AB's EPS (Basic) for the three months ended in Mar. 2026 was €-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.08.


Oncopeptides AB  (FRA:OND) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Oncopeptides AB EPS without NRI Related Terms


Oncopeptides AB EPS without NRI Historical Data

* Premium members only.

The historical data trend for Oncopeptides AB's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncopeptides AB EPS without NRI Chart

Oncopeptides AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.17 -0.24 -0.22 -0.14 -0.09

Oncopeptides AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.02 -0.02 -0.02 -0.01

FRA:OND vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Oncopeptides AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncopeptides AB PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's PE Ratio without NRI falls into.


FRA:OND
28GF Score
Oncopeptides AB FRA:OND
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncopeptides AB EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €-0.08 mean?
Oncopeptides AB (FRA:OND) has a EPS without NRI of €-0.08 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Oncopeptides AB and its competitors. According to the industry distribution chart, Oncopeptides AB ranks #427 out of 1166 companies in the Biotechnology industry, placing it in the top 36.6%.
Is Oncopeptides AB's EPS without NRI too high?
Oncopeptides AB's current EPS without NRI is €-0.08. Based on the distribution chart, Oncopeptides AB ranks #427 out of 1166 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oncopeptides AB has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncopeptides AB ranks #427 out of 1166 companies for EPS without NRI. This puts Oncopeptides AB in the upper half of its industry. The industry median EPS without NRI is 16.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.65, based on 1,166 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Oncopeptides AB and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncopeptides AB's current EPS without NRI is €-0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (FRA:OND) is currently considered Possible Value Trap. The stock's GF Value™ is €0.38, compared to a current price of €0.15 — trading 60.9% below its estimated fair value. The current EPS without NRI is €-0.08. Oncopeptides AB's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Oncopeptides AB (FRA:OND), the current EPS without NRI is €-0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncopeptides AB (FRA:OND) Overvalued in 2026?

Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued. The current stock price of €0.15 is trading 60.9% below its estimated GF Value™ of €0.38. GuruFocus considers Oncopeptides AB to be Possible Value Trap.

Key valuation signals for FRA:OND:

  • EPS without NRI: €-0.08
  • GF Value™: €0.38 vs. price of €0.15 (60.9% below fair value)
  • GF Score™: 28/100 with 3 warning signs

No single metric tells the full story. See the FRA:OND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oncopeptides AB Business Description

Other Exchanges ONCO:SwedenONCOs:UK0RN4:UK
Address Luntmakargatan 46, Stockholm, SWE, SE-111 37
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
28GF Score

Get the complete analysis for FRA:OND

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price
€0.38
GF Value